311 related articles for article (PubMed ID: 29627234)
21. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70(359-610)) fusion protein against influenza virus infection in mice.
Attaran H; Nili H; Tebianian M
Virol Sin; 2014 Aug; 29(4):218-27. PubMed ID: 25160757
[TBL] [Abstract][Full Text] [Related]
23. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.
Dhakal S; Renu S; Ghimire S; Shaan Lakshmanappa Y; Hogshead BT; Feliciano-Ruiz N; Lu F; HogenEsch H; Krakowka S; Lee CW; Renukaradhya GJ
Front Immunol; 2018; 9():934. PubMed ID: 29770135
[TBL] [Abstract][Full Text] [Related]
24. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
25. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
[TBL] [Abstract][Full Text] [Related]
26. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
[TBL] [Abstract][Full Text] [Related]
27. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
28. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
[TBL] [Abstract][Full Text] [Related]
29. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
30. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
31. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
33. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
34. Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study.
Rungrojcharoenkit K; Sunintaboon P; Ellison D; Macareo L; Midoeng P; Chaisuwirat P; Fernandez S; Ubol S
PLoS One; 2020; 15(8):e0237218. PubMed ID: 32760143
[TBL] [Abstract][Full Text] [Related]
35. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
36. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
37. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine.
Jazi MH; Dabaghian M; Tebianian M; Gharagozlou MJ; Ebrahimi SM
Virus Res; 2012 Aug; 167(2):219-25. PubMed ID: 22609252
[TBL] [Abstract][Full Text] [Related]
38. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.
Kammoun H; Roux X; Raze D; Debrie AS; De Filette M; Ysenbaert T; Mielcarek N; Saelens X; Fiers W; Locht C
PLoS One; 2013; 8(3):e59198. PubMed ID: 23555631
[TBL] [Abstract][Full Text] [Related]
40. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
